Press Releases

KemPharm® is a clinical stage, specialty pharmaceutical company engaged in the development and discovery of proprietary prodrugs that are designed to be improved versions of widely prescribed and FDA approved products.

Press Releases

News Releases

Date Title and Summary
Toggle Summary KemPharm Announces Amendment to Licensing Agreement with Gurnet Point Capital Affiliate Following FDA Approval of AZSTARYS™
Amendment Increases Total Potential Regulatory and Sales Milestone Payments to $590 Million , and Adds a New Top-Level Tier for Royalties on U.S. Net Sales Conference Call and Live Audio Webcast Scheduled for Today, Thursday, April 8 , at 4:30 p.m. ET CELEBRATION, Fla.
Toggle Summary KemPharm Reports Fourth Quarter and Full-Year 2020 Financial Results
Corporate and Regulatory Highlights: AZSTARYS™ NDA approved by the FDA on March 2, 2021 Co-hosted “KP415 Market Opportunity and Commercialization Strategy” Investor Event with Corium, Inc. Received FDA clearance to initiate KP879 clinical program for the treatment of Stimulant Use Disorder
Toggle Summary KemPharm to Report Fourth Quarter and Full Year 2020 Financial Results
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Thursday, March 11, 2021 , 4:30 p.m. ET CELEBRATION, Fla. , March 09, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary
Toggle Summary KemPharm to Present at the 33rd Annual Roth Conference
CELEBRATION, Fla. , March 04, 2021 (GLOBE NEWSWIRE) -- KemPharm , Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that Travis C. Mickle , Ph.D., President and CEO of KemPharm, will present at the 33 rd Annual
Toggle Summary KemPharm Announces FDA Approval of AZSTARYS™ (serdexmethylphenidate and dexmethylphenidate capsules, for oral use, CII), A New Once-Daily Treatment for ADHD
Conference Call and Live Audio Webcast Scheduled for Tomorrow, Wednesday, March 3 , at 8:30 a.m. ET CELEBRATION, Fla. , March 02, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today
Toggle Summary KemPharm Receives FDA Clearance to Initiate KP879 Clinical Program for the Treatment of Stimulant Use Disorder
Financial Restructuring and Nasdaq Re-Listing Process Completed CELEBRATION, Fla. , Jan. 27, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced that the U.S.
Toggle Summary KemPharm’s KP415 and Serdexmethylphenidate (SDX) Prodrug to be Featured in Multiple Sessions at the 2021 APSARD Virtual Conference
Combination of Oral and Poster Presentations Scheduled for January 15, 2021 CELEBRATION, Fla. , Jan. 14, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced that research
Toggle Summary KemPharm Participating in BIO @ JPM and Fierce JPM Week 2021 Virtual Events During “J.P. Morgan Week 2021”
CELEBRATION, Fla. , Jan. 13, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that the company is participating in BIO @ JPM and Fierce JPM Week 2021.  Both events are being
Toggle Summary KemPharm Announces Pricing of $50 Million Public Offering of Common Stock and Warrants and Uplisting to The Nasdaq Capital Market
Common stock will begin trading on The Nasdaq Capital Market under the ticker symbol “KMPH” today, January 8, 2021 CELEBRATION, Fla. , Jan. 08, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary
Toggle Summary KemPharm Announces 1-for-16 Reverse Stock Split
CELEBRATION, Fla. , Dec. 23, 2020 (GLOBE NEWSWIRE) -- KemPharm, Inc. (OTCQB: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that the Company's Board of Directors has approved a 1-for-16 reverse stock split of its shares of